1
General presentation A Newly-approved safe ingredient for effective
weight management promotion
April 2011
2
Table of contents
Designed for consumers
Scientific evidence
Regulatory status
Technological data
Marketing potential
Conclusion
2
Designed for consumers
4
Chromax® is a patented salt of trivalent chromium (Cr3+) and tri-picolinic acid,
also known as chromium picolinate, containing 12% of pure chromium
Chromax® is the purest chromium picolinate on the market
recognized as a quality reference.
As a safe product and a source of bioavailable chromium,
Chromax® made the proof of its efficiency though numerous
clinical studies
What is Chromax®?
A newly-approved safe ingredient for effective
weight management promotion
Chromax® is the only chromium picolinate approved by the EU.
Its high purity and safety testing makes it superior to other
chromium products on the market.
Designed for consumers
3
5
Chromax® is made from pure compounds using proprietary manufacturing and
quality control processes to produce a superior high purity product.
Some other chromium products on the market actually contain
less than 70% pure chromium picolinate.
The National Toxicology Program (USA) conducted safety
studies, using purified chromium picolinate, which confirmed
the long-term high dose safety of the pure chromium
picolinate compound. (Rhodes et al, 2004, Stout et al, 2009)
The safety studies were repeated and resulted in clear demonstration of the safety
of Chromax®. (See Gudi et al, 2005; Slesinski et al, 2005).
A pure and top-quality product for a superior safety
How Chromax® makes the difference?
6
A pure and top-quality product for a superior safety
Designed for consumers
Chromax® is the only chromium picolinate currently on the market to benefit from
a positive opinion issued by the EFSA (European Food Safety Authority) http://ec.europa.eu/food/food/biotechnology/novelfood/index_en.htm
Chromax® chromium picolinate have the benefit of knowing that this is the form of
chromium picolinate used as a standard for approval and is also the product used in
safety and efficacy studies submitted to Regulatory authorities
When purchasing Chromax® chromium picolinate, the industry is assured of using
chromium picolinate that meets and exceeds the EU standards
Customers are better protected from lower quality products claiming to be high
purity chromium picolinate since compound purity testing is required
Chromax® is the quality reference on the market and insured a high
safety contrary other products
How Chromax® makes the difference?
4
7
The bioavailability of Chromax® has been clinically demonstrated as significantly
better compared to other sources of chromium
Consumers now have a higher confidence that Chromax® matches the high quality
standards used in the efficacy studies performed over the last 15 years
Chromax® approach contributed to raise mineral compounds’ global quality
standards for inclusion in dietary supplements and functional foods
Chromax® has been clinically demonstrated as a safe and effective product in over
15 published studies.
Chromax®: A safe and effective solution
you can rely upon Superior chromium bioavailability and efficacy
On the weight management market, consumers are often eager to find
more reliable solutions . Indeed, they often need to choose between
safety or efficacy : When they choose Chromax®, consumers are ensured
have both a safe and efficient weight management solution.
Designed for consumers
Scientific evidence
5
9
Chromax®: Clinically proven efficacy
Chromax®: increased chromium bioavailability
2 scientific studies on chromium concentration in urine
1 scientific study on chromium concentration in tissues
Chromax®: carbohydrate metabolism regulation
More than 15 clinical studies on insulin sensitivity and glycemia regulation
Chromax®: weight management promotion
4 clinical studies on weight and fat mass loss
1 clinical study on satiety
1 clinical study on carbohydrate craving
Scientific evidence
More than 15 clinical studies on over 1 800 volunteers
10
Chromax®: Clinically proven efficacy
1. Stability and absorption of chromium. Anderson et al., 2004.
Volunteers: 6 mixed volunteers
Duration: 48h
Dosage: 200 µg/day of pure chromium under the form of chromium nicotinate, chromium chloride or chromium picolinate (Chromax®, 1.6 mg/day)
Scientific evidence
Increased chromium bioavailability
2. Comparison of acute absorption of chromium supplements. DiSilvestro and Dy, 2007.
Volunteers: 12 women
Duration: 24h
Dosage: 200 µg/day of pure chromium, under the form of chromium polynicotinate, chromium nicotinate-glycinate, chromium chloride or chromium picolinate (Chromax®, 1.6 mg/day)
6
11
Chromax®: Clinically proven efficacy
1. Stability and absorption of chromium. Anderson et al., 2004.
Scientific evidence
Increased chromium bioavailability
2. Comparison of acute absorption of chromium supplements. DiSilvestro and Dy, 2007.
0
500
1000
1500
2000
2500
1
Uri
nary
chro
miu
m (
ng/day)
Basal loss Chromium nicotinate Chromium chloride Chromium picolinate
* * p<0.05
0
100
200
300
400
500
600
% increase of urinary chromium after 24h
% incre
ase
of
uri
nary
chro
miu
m a
fter
24h
Chromium polynicotinate Chromium nicotinate-glycinate Chromium chloride Chromax®
* * p<0.05
Chromax® is significantly more abundant in urine than chromium nicotinate and chromium chloride, which indirectly shows that chromium picolinate is more absorbed
12 12
Chromax®: Clinically proven efficacy
Subjects: 55 male Wistar rats
Duration: 3 weeks
Dosage: 5 µg/g of diet/day of pure chromium,
under the form of chromium chloride,
chromium nicotinate or chromium picolinate
(Chromax®, 0.04 mg/g of diet/day)
Chromax® is significantly more concentrated
in liver, muscle and heart than chromium
nicotinate and chromium chloride
Scientific evidence
Increased chromium bioavailability
These studies demonstrate a significant difference in chromium
bioavailability between Chromax® and other sources of chromium
0
5
10
15
20
25
30
35
40
45
50
Liver Muscle Heart
Control CrCl CrNic CrPic
ng/m
g d
ry w
eig
ht
3. Dietary chromium effects on tissue chromium concentrations and
chromium absorption in rats. Anderson et al., 1996.
7
13
Chromax®: Clinically proven efficacy
Scientific evidence
Carbohydrate metabolism regulation
Enhancement in Insulin Sensitivity in Healthy
Volunteers following supplementation with Chromium
Picolinate. Morris et al, 1998
Volunteers: 6 healthy subjects
Duration: 10 weeks
Dosage: 1.6 mg/day of Chromax®, equivalent to 200 µg/day of pure chromium
Results:
• Significant increase of fasting levels of plasma chromium during the 5 first
weeks
• Fasting Blood glucose levels tends to decrease during the supplementation
14
Chromax®: Clinically proven efficacy
Scientific evidence
Carbohydrate metabolism regulation
Enhancement in Insulin Sensitivity in Healthy
Volunteers following supplementation with Chromium
Picolinate. Morris et al, 1998
Chromax® significantly reduces Insulin-Resistance at the dosage of 1.6 mg/day
Chromax® Significantly decrease fasting Insulin at the dosage of 1.6 mg/day
0.0
0.5
1.0
1.5
2.0
2.5
3.0
PreCr 1 2 3 4 5 6 7 8 9 10 Off 1 Off 2
Insu
lin
Resis
tan
ce
(HO
MA
)
Weeks
* *
** ** ** ** **
8
15
Chromax®: Clinically proven efficacy
Others studies on insulin sensitivity and glycemia regulation.
At the dosage of 200µg of pure chromium per day, 5 clinical studies showed very significant results:
Carbohydrate metabolism regulation
Scientific evidence
Study Volunteers Duration Dosage(1) Results
Lucidi, 2005 10 with PCOS(3) 4 months 1.6 mg (200 µg) glucose tolerance
Ghosh, 2002 50 type 2 diabetics with medication 3 months 1.6 mg (200 µg) glycated hemoglobin(2) (*p<0.05)
fasting glycemia (***p<0.001)
Anderson,
1997
180 type 2 diabetics with
medication
4 months 1.6 mg (200 µg)
and 8.3 mg
(1000 µg)
glycated hemoglobin(2) (*p<0.05)
fasting glycemia (*p<0.05)
insulin production (*p<0.05)
Ravina, 1995 162 type 1 and 2 diabetics with
med.
3 months 1.6 mg (200 µg) insulin sensitivity (***p<0.001)
Evans, 1989 11 type 2 diabetics with medication 1.5 month 1.6 mg (200 µg) glycated hemoglobin(2) (*p<0.05) (1) dosage of Chromax® / day (equivalent dosage of pure chromium / day) (2) glycated hemoglobin (HbA1c) is the reference biological marker for glycemia monitoring in diabetic patients (3) PCOS = polycystic ovary syndrome, which is strongly correlated with insulin resistance and diabetes
In other dosages, more than 15 studies were conducted on Chromax® to prove this effect.
16 16
Chromax® potentiates insulin function for a clinical
proven action on carbohydrate metabolism
Chromax® enhances the activity of insulin receptors on
cells membranes and thus increases insulin sensitivity and
glucose storage in muscle cells
Chromax®, by promoting healthy blood sugar
metabolism, reduces the storage of fat and contributes to
healthy weight management
Chromax®: Clinically proven efficacy
Carbohydrate metabolism regulation
Scientific evidence
9
17 17
Chromax®: Clinically proven efficacy
STUDY 1
• Volunteers: 10 healthy men
• Activity: weight lifting program, 2 periods/week
• Duration: 40 days
• Dosage: 1.6 mg/day of Chromax®, equivalent to
200 µg/day of chromium
• Results:
Significantly increase of lean body mass
(p=0.019)
Increase of body weight was due essentially to
increase in lean body mass
Scientific evidence
Weight management promotion/ Fat mass loss
STUDY 2
• Volunteers: 31 football players
• Activity: weight-training 1 hour/day
• Duration: 6 weeks
• Dosage: 1.6 mg/day of Chromax®, equivalent to
200 µg/day of chromium
• Results:
Significantly increase of lean body mass
(p=0.031)
Significant decrease in the total fat (p=0.001)
Chromium Picolinate and Body composition. Evans et al, 1989: 2 separate studies
Change in Lean Body Mass
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
1
Treatment
kg
CrPic
Placebo
*
***
*p<0.05
***p<0.005
18
Chromax®: Clinically proven efficacy
Scientific evidence
Weight management promotion / Fat mass loss
2. Effects of chromium picolinate supplementation on body composition. Kaats et al., 1998.
Volunteers:
• 154 mixed volunteers
• Inclusion criteria: overweight or obese (mean BMI = 30)
Duration: 72 days
Dosage: 1.6 to 3.3 mg/day of Chromax®, equivalent to 200 to 400 µg/day of pure
chromium
10
19
2. Effects of chromium picolinate supplementation on
body composition. Kaats et al., 1998.
BCI (Body Composition Index) = net difference between lean mass gain and fat mass loss
-6
-4
-2
0
2
4
6
8
Weight loss (kg) Fat mass loss (kg) Lean mass loss (kg) Fat mass loss (% body weight) BCI (kg)
Placebo 1.6 mg/day of Chromax® 3.3 mg/day of Chromax®
Chromax®: Clinically proven efficacy
Scientific evidence
*
* p<0.05
** p<0.01
*** p<0.005
Weight management promotion/Fat mass loss
* ***
* ***
*** **
20
2. Effects of chromium picolinate supplementation on
body composition. Kaats et al., 1998.
Trend of body mass loss at 1.6 mg/day of Chromax®
Significant fat mass loss from 1.6 mg/day of Chromax®
No significant lean mass loss
Significant decrease of fat mass proportion from 1.6 mg/day of Chromax®
Significant improvement of body composition index from 1.6 mg/day of Chromax®
Chromax®: Clinically proven efficacy
Scientific evidence
Weight management promotion/Fat mass loss
Chromax® shows significant results on weight and fat mass loss
while preserving lean mass, from the dosage of 2 mg/day
11
21
Chromax®: Clinically proven
efficacy
Volunteers:
• 42 women
• Inclusion criteria: BMI 25-40, reporting intense carb craving
Duration: 8 weeks
Dosage: 8.3 mg/day of Chromax®,
equivalent to 1 000 µg/day of pure
chromium
Scientific evidence
Weight management promotion/ Satiety
0
50
100
150
200
250
300
350
400
After 1 week After 8 weeks
Food inta
ke r
educt
ion (
kca
l)Placebo Chromax®
Chromax® significantly reduces
food intake at the dosage of 8.3 mg/day
3. Effects of chromium picolinate on food intake and satiety. Anton et al., 2008.
22
Chromax®: Clinically proven
efficacy
Scientific evidence
Weight management promotion/ Carbohydrate craving
Volunteers:
• 75 mixed volunteers
• Inclusion criteria: experiencing
atypical depression
Duration: 8 weeks
Dosage: 5 mg/day of Chromax®,
equivalent to 600 µg/day of pure
chromium
4. Exploratory trial of chromium picolinate in atypical depression: effect on carbohydrate craving. Docherty et al., 2005.
0
0.5
1
1.5
2
0 2 weeks 4 weeks 6 weeks 8 weeks
Score
Hunger Carb craving
Chromax® significantly decreases
hunger and carb craving from the dosage
of 5 mg/day
12
23 23
Chromax®: Clinically proven efficacy
Chromax® has greater absorption of chromium and increased bioavailability in scientifically validated studies that have been approved by regulatory authorities worldwide
Chromax® as « chromium picolinate is among the most bioavailable forms of chromium » (The EFSA Journal (2009) 1113, 1-41)
Chromax® has clinically proven efficacy on the regulation of carbohydrate metabolism at the dosage of 2 mg/day
Chromax® is a safe and effective ingredient for success in your weight management products
Scientific evidence
Conclusions
Regulatory status
13
25
Is Chromax® authorized for use?
A food grade ingredient
USA:
• Authorized for use in food supplements
• Authorized for use in functional bars and beverages (GRAS status)
Europe*:
• Authorized for use in foodstuffs for particular
nutritional uses and foods intended for the
general population (including food supplement)
(The EFSA Journal 2010;8(12):1882) * Recommended dosage according to the current national regulations
Asia:
• Authorized for use in food supplements in most countries: Australia, Indonesia,
Malaysia, Singapore, Taiwan, Thailand,…
• Authorized for use in functional foods in most countries:
Indonesia, Singapore, Taiwan, Thailand,…
Regulatory status
A clear and well-defined regulatory status
26
A health claim authorization
FDA approval for a qualified health claim regarding the
reduction of risk of insulin resistance and type II diabete
A clear label
Suggested labeling: « Chromium picolinate » (« Picolinate de chrome »)
Regulatory status
A clear and well-defined regulatory status
Is Chromax® authorized for use?
Chromax® benefits from our regulatory expertise.
Please feel free to contact us for further information.
14
Technological data
28 28
Chromax® - Purity
Analytical comparison of marketed chromium compounds
Chromium #1
(multiple compounds)
Chromax ®
(pure chromium picolinate)
Technological data
15
29
How can Chromax® be used?
Chromax® is a fine and homogeneous powder. It is
red colored, water-soluble and pH-stable.
Thanks to its high density and to its low dosage (2 mg/day), Chromax® can easily be
implemented into various matrices:
• Food supplements: tablets, capsules, softgels, gums,…
• Functional foods: bars, dairies, chocolate, beverages,…
Several applications have already been tested by Ingredia Nutritional.
Please feel free to contact us for further information.
Technological data
Chromax® is a ready-to-use ingredient that will make the
difference in your food supplement or functional food
A flexible ingredient
30
In coherence with WHO (World Health Organisation) and EFSA
conclusions, Ingredia Nutritional recommends a dosage of 2 mg/day
of Chromax®, which is equivalent to 240 µg/day of pure chromium
The WHO and EFSA concluded that pure chromium is completly
safe up to 250 µg/day and validated Chromax® complete safety
How can Chromax® be used?
Recommended dosage
For consumer, only 2 mg/day of Chromax® will provide you with
all the benefits of chromium without any concern for safety
16
Marketing potential
32
Marketing potential
Chromax®: Successful in applications
Chromax® shot A Newly-Approved Safe Ingredient for Effective Weight
Management. Chromax® is the first chromium picolinate that meets the high
quality standards required in the EU. Chromax® potentiates insulin function for a
clinically proven action on carbohydrate metabolism and weight management
Glycemia optimize Helps you control blood sugar level. Chromax® acts on the moderation of the glycemic answer and have an
activating action on insulin. With Glycemia optimize, you can go eating the
food you like without thinking of consequences
Fit&Slim Speed’up your metabolism. FIT&SLIM is a drink designed for
people wishing, in addition to regular physical activity, to manage their
weight and get slim. Chromax® stimulates fat elimination and enables to
develop a firm, fit and slim body.
One bioactive for multiple applications!
17
33
Chromax®: Successful in applications
One bioactive for multiple applications!
Eat Less Helps you reach a healthy diet naturally. Eat less is an original
formulation composed of specific high-end chromium picolinate: Chromax®. It has
a double action both on physical satiety and on hormonal signals. This delicious
beverage allows you to experience satiety and reduce your food intake, in order to
reach you the silhouette of your dreams.
Stop snacking Control food craving for a successfull diet Snacking is the
first cause of failure during long-time diet. Thanks to its exclusive ingredient
Chromax®, which act on the carbohydrate metabolism, Stop snacking will help you
get the strength to resist temptation and achieve a successful diet.
Chromax® BMR (Body Mass Reduction) Your partner for an athletic
body With Chromax®, lose your fat mass while preserving your muscular one.
Coupled with an intense physical activity, Chromax® BMR will help you get rid of
excess body fat without sacrificing your muscles.
Conclusion
18
35 35
Why choose Chromax®?
Chromax®
Conclusion
Clinically proven
efficacy on carbohydrate
metabolism regulation,
increased bioavailability,
and weight management
Easy implementation in dietary
supplements and food matrices
The most effective at the best price
The best value for money
of the market!
The purest and the safest chromium picolinate
on the market of the chrome products
Chromax® is the quality
reference and has high
safety compared to other
products
Chromax® established its
proof of efficacy though
numerous clinical studies
36
References
Anderson, R.A. ; Bryden, N.A. ; Polansky, M.M. ; Gautschi, K. (1996). Dietary chromium effects on
tissue chromium concentrations and chromium absorption in rats. The Journal of Trace Elements in
Experimental Medicine ; 9 ; 11-15.
Anderson, R.A. ; Cheng, N. ; Bryden, N.A. ; Polansky, M.M. ; Chi, J. ; Feng, J. (1997). Elevated
intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2
diabetes. Diabetes ; 46 ; 1786-1791.
Anderson, R.A. ; Polansky, M.M. ; Bryden, N.A. (2004). Stability and absorption of chromium and
absorption of chromium histidinate complexes by humans. Biological Trace Element Research ; 101 ;
211-218.
Anton, S.D. ; Morrison, C.D. ; Cefalu, W.T. ; Martin, C.K. ; Coulon, S. ; Geiselman, P. ; Han, H. ;
White, C.L. ; Williamson, D.A. (2008). Effects of chromium picolinate on food intake and satiety.
Diabetes Technology and Therapeutics ; 10(5) ; 405-412.
Bahadori, B. ; Wallner, S. ; Hacker, C. ; Boes, U. ; Komorowski, J.R. ; Wascher, T.C. (1999).
Effects of chromium picolinate on insulin levels and glucose control in obese patients with type-II
diabetes mellitus. Diabetes ; 48 ; A349.
Cefalu, W.T. ; Bell-Farrow, A.D. ; Stegner, J. ; Wang, Z.Q. ; King, T. ; Morgan, T. ; Terry, J.G.
(1999). Effect of chromium tripicolinate on insulin sensitivity in vivo. The Journal of Trace Elements
in Experimental Medicine ; 12 ; 71-83.
Conclusion
19
37
References
Cheng, N. ; Zhu, X. ; Shi, H. ; Wu, W. ; Jiamin, C. ; Jianying, C. ; Anderson, R.A. (1999). Follow-
up survey of people in China with type 2 diabetes mellitus consuming supplemental chromium. The
Journal of Trace Elements in Experimental Medicine ; 12 ; 55-60.
DiSilvestro R.A. ; Dy, E. (2007). Comparison of acute absorption of commercially available
chromium supplements. The Journal of Trace Elements in Medicine and Biology ; 21 ; 120-124.
Docherty, J.P. ; Sack, D.A. ; Roffman, M. ; Finch, M. ; Komorowski, J.R. (2005). A double-blind,
placebo-controlled, exploratory trial of chromium picolinate in atypical depression: effect on
carbohydrate craving. Journal of Psychiatric Pratice ; 11(5) ; 302-314.
Evans, G.W. (1989). The effect of chromium picolinate on insulin controlled parameters in humans.
Int. J. Biosocial. Med. Res. ; 11 ; 163-180.
Feng, J ; Lin, D. ; Zheng, A. ; Cheng, N. (2002). Chromium picolinate reduces insulin requirement
in people with type 2 diabetes mellitus. Diabetes ; 51 ; A469.
Ghosh, D. ; Bhattacharya, B. ; Mukherjee, B. ; Manna, B. ; Sinha, M. ; Chowdhury, J. ;
Chowdhury, S. (2002). Role of chromium supplementation in Indians with type 2 diabetes mellitus. J.
Nutr. Biochem. ; 13 ; 690-697.
Jovanovic-Peterson, L. ; Gutlerrez, M. ; Peterson, C.M. (1999). Chromium supplementation for
women with gestational diabetes mellitus. The Journal of Trace Elements in Experimental Medicine ;
12 ; 91-97.
Conclusion
38
References
Kaats, G.R. ; Blum, K. ; Fisher, J.A. ; Adelman, J.A. (1998). Effects of chromium picolinate
supplementation on body composition: a randomized, double-masked, placebo-controlled study. Current
Therapeutic Research ; 57(10) ; 747-756.
Lucidi, R.S. ; Thyer, A.C. ; Easton, C.A. ; Holden, A.E.C. ; Schenken, R.S. ; Brzyski, R.G. (2005).
Effect of chromium supplementation on insulin resistance and ovarian and menstrual cyclicity in women
with polycystic ovary syndrome. Fertil. Steril. ; 84 ; 1755-1757.
Lydic, M.L. ; McNurlan, M. ; Bembo, S. ; Mitchell, L. ; Komaroff, E. ; Gelato, M. (2006). Chromium
picolinate improves insulin sensitivity in obese subjects with polycystic ovary syndrome. Fertil. Steril. ;
86 ; 243-246.
Martin, J. ; Wang, Z.Q. ; Zhang, X.H. ; Wachtel, D. ; Volaufova, J. ; Matthews, D.E. ; Cefalu, W.T.
(2006). Chromium picolinate supplementation attenuates body weight gain and increases insulin
sensitivity in subjects with type 2 diabetes. Diabetes Care ; 29(8) ; 1826-1832.
Morris, B.W. ; Kouta, S. ; Robinson, R. ; MacNeil, S. ; Heller, S. (2000). Chromium supplementation
improves insulin resistance in patients with type 2 diabetes mellitus. Diabet. Med. ; 17 ; 684-685.
Rabinovitz, H. ; Leibovitz, A. ; Madar, Z. ; Gabai, G. ; Habot, B. (2000). Blood glucose and lipid
levels following chromium supplementation in diabetic elderly patients on a rehabilitation program.
Gerontologist ; 40.
Conclusion
20
39
References
Ravina, A. ; Slezak, L. ; Rubal, A. ; Mirsky, N. (1995). Clinical use of the trace element chromium
(III) in the treatment of diabetes mellitus. The Journal of Trace Elements in Experimental Medicine ; 8 ;
183-190.
Ravina, A. ; Slezak, L. ; Mirsky, N. ; Bryden, N.A. ; Anderson, R.A. (1999). Reversal of
corticosteroid-induced diabetes mellitus with supplemental chromium. Diabet. Med. ; 16 ; 164-167.
Vrtovec, M. ; Vrtovec, B. ; Briski, A. ; Kocijancic, A. ; Anderson, R.A. ; Radovancevic, B. (2005).
Chromium supplementation shortens QTc interval duration in patients with type 2 diabetes mellitus.
American Heart Journal ; 149(4) ; 632-636.
Wang, Z.Q. ; Qin, J. ; Martin, J. ; Zhang, X.H. ; Sereda, O. ; Anderson, R.A. ; Pinsonat, P. ; Cefalu,
W.T. (2007). Phenotype of subjects with type 2 diabetes mellitus may determine clinical response to
chromium supplementation. Metabolism ; 56 ; 1652-1655.
Conclusion
40
www.ingredia-nutritional.com
Thank you for your attention!
Top Related